<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Elevated endothelin (ET)-1 has been implicated in cerebrovascular complications following brain trauma characterized by dysregulation of endothelial nitric <z:chebi fb="177" ids="25741,29356">oxide</z:chebi> synthase (eNOS), protein kinase C (PKC), and cerebral function </plain></SENT>
<SENT sid="1" pm="."><plain>Recently, vascular expression of PPARalpha has been observed and suggested to improve vascular dysfunction </plain></SENT>
<SENT sid="2" pm="."><plain>We speculate that activation of PPARalpha in cerebral microvessels can improve <z:e sem="disease" ids="C0262405" disease_type="Disease or Syndrome" abbrv="">cerebral dysfunction</z:e> following trauma, and we tested the hypothesis that activation of cerebral endothelial peroxisome proliferator-activated receptor (PPAR)alpha will attenuate ET-1 production via a mechanism involving nitric <z:chebi fb="177" ids="25741,29356">oxide</z:chebi> (NO) and PKC </plain></SENT>
<SENT sid="3" pm="."><plain><z:chebi fb="0" ids="8116">Phorbol</z:chebi> 12-<z:chebi fb="0" ids="30807">myristate</z:chebi> 13-<z:chebi fb="49" ids="30089,47622">acetate</z:chebi> (<z:chebi fb="1" ids="53780">PMA</z:chebi>) (1 microM), bradykinin (BK, 1 microM), <z:chebi fb="0" ids="2719,48432">angiotensin II</z:chebi> (AII, 1 microM), or <z:chebi fb="0" ids="35143">hemoglobin</z:chebi> (Hem, 10 microM) increased ET-1 levels by 24-, 11.4-, 3.6-, or 1.3-fold increasing ET-1 levels from 0.36 +/- 0.08 to 8.6 +/- 0.8, 4.1 +/- 0.7, 1.30 +/- 0.1, or 0.47 +/- 0.03 fmol/microg protein (p &lt; 0.05), respectively </plain></SENT>
<SENT sid="4" pm="."><plain><z:chebi fb="0" ids="3750">Clofibrate</z:chebi> (10 microM) reduced basal ET-1 from 0.36 +/- 0.08 (control) to 0.03 +/- 0.01 and blunted vasoactive agent-induced increase to 0.12 +/- 0.07 (<z:chebi fb="1" ids="53780">PMA</z:chebi>), 0.6 +/- 0.04 (BK), 0.25 +/- 0.03 (AII), or 0.12 +/- 0.03 (Hem) fM/microg protein (p &lt; 0.05) </plain></SENT>
<SENT sid="5" pm="."><plain><z:chebi fb="0" ids="16467,29952">L-arginine</z:chebi> <z:chebi fb="36" ids="29309">methyl</z:chebi> <z:chebi fb="21" ids="35701">ester</z:chebi> (100 microM) inhibited <z:chebi fb="0" ids="3750">clofibrate</z:chebi>-induced reduction in basal ET-1 production </plain></SENT>
<SENT sid="6" pm="."><plain><z:chebi fb="0" ids="3750">Clofibrate</z:chebi> increased PPARalpha expression, accompanied by increased NO production and eNOS expression </plain></SENT>
<SENT sid="7" pm="."><plain>PKC inhibition by calphostin C (10 microM) blocked these effects, whereas activation by <z:chebi fb="1" ids="53780">PMA</z:chebi> reduced basal PPARalpha expression </plain></SENT>
<SENT sid="8" pm="."><plain>Thus, PPARalpha activation attenuated ET-1 production by agents that mediate brain injury through mechanisms that probably result from PPARalpha-induced increase in eNOS expression/NO production and complex PKC signaling pathways </plain></SENT>
<SENT sid="9" pm="."><plain>Therefore, PPARalpha activators can be appropriate therapeutic agents to alleviate cerebrovascular dysfunction following <z:e sem="disease" ids="C0265110" disease_type="Disease or Syndrome" abbrv="">cerebral vasospasm</z:e> </plain></SENT>
</text></document>